NCT02258659 - Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2014

Primary Completion Date

September 6, 2024

Study Completion Date

September 6, 2024

Conditions

Human Papilloma Virus InfectionStage III Squamous Cell Carcinoma of the OropharynxStage IVA Squamous Cell Carcinoma of the OropharynxStage IVB Squamous Cell Carcinoma of the Oropharynx

Interventions

DRUG

paclitaxel albumin-stabilized nanoparticle formulation

Given IV

DRUG

carboplatin

Given IV

RADIATION

radiation therapy

Undergo radiation therapy

DRUG

paclitaxel

Given IV

DRUG

fluorouracil

Given IV

DRUG

hydroxyurea

Given PO

DRUG

cisplatin

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

quality-of-life assessment

Ancillary studies

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER